Skip to main content
. 2022 Jan 14;26(4):1083–1094. doi: 10.1111/jcmm.17163

FIGURE 2.

FIGURE 2

Associations between GIST FGL2 protein expression with recurrence‐free survival (A), overall survival (B), and GIST‐specific survival (C) in the western Sweden population‐based series. Associations between GIST FGL2 protein expression with recurrence free survival (D), overall survival (E) and recurrence‐free survival stratified by the duration of adjuvant imatinib (either 12 months or 36 months) (F) in the SSGXVIII trial series. The patients censored are indicated with a bar